Insider Buying: InspireMD, Inc. (NYSE:NSPR) CEO Purchases 10,330 Shares of Stock

Key Points

• CEO Marvin Slosman of InspireMD, Inc. acquired 10,330 shares of the company's stock at an average price of $2.42, increasing his total holdings to 2,420,866 shares.
• InspireMD's stock has a 52-week range of $1.99 to $3.80, with a current price of $2.69 and a market capitalization of $82.41 million.
• Notable institutional investors, including Renaissance Technologies and Northern Trust Corp, have recently increased their stakes in InspireMD, contributing to institutional ownership of 44.78%.

InspireMD, Inc. (NYSE:NSPR - Get Free Report) CEO Marvin Slosman acquired 10,330 shares of InspireMD stock in a transaction on Wednesday, July 30th. The shares were bought at an average price of $2.42 per share, for a total transaction of $24,998.60. Following the completion of the purchase, the chief executive officer directly owned 2,420,866 shares in the company, valued at $5,858,495.72. The trade was a 0.43% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

InspireMD Trading Down 2.6%

NYSE NSPR traded down $0.07 during trading on Tuesday, reaching $2.60. The company's stock had a trading volume of 48,585 shares, compared to its average volume of 103,497. The stock has a market capitalization of $79.65 million, a PE ratio of -3.47 and a beta of 0.60. The business has a 50-day moving average price of $2.43 and a 200-day moving average price of $2.61. InspireMD, Inc. has a 1-year low of $1.99 and a 1-year high of $3.80.

Institutional Investors Weigh In On InspireMD

Institutional investors and hedge funds have recently bought and sold shares of the business. Huntleigh Advisors Inc. lifted its position in InspireMD by 5.8% during the 2nd quarter. Huntleigh Advisors Inc. now owns 124,228 shares of the company's stock worth $282,000 after buying an additional 6,821 shares in the last quarter. Brown Advisory Inc. acquired a new stake in shares of InspireMD in the 1st quarter valued at approximately $27,000. Uniting Wealth Partners LLC acquired a new stake in shares of InspireMD in the 1st quarter valued at approximately $27,000. Renaissance Technologies LLC acquired a new stake in shares of InspireMD in the 4th quarter valued at approximately $27,000. Finally, XTX Topco Ltd bought a new stake in InspireMD during the 1st quarter worth approximately $38,000. Institutional investors own 44.78% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NSPR. Wall Street Zen started coverage on shares of InspireMD in a research report on Monday, May 5th. They issued a "sell" rating on the stock. Piper Sandler lowered their price objective on shares of InspireMD from $4.50 to $4.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.